More Post from the Author
- Broadridge Schedules Webcast and Conference Call to Review Fourth Quarter and Fiscal Year 2025 Results on August 5, 2025
- AveriSource announces availability of AI-Powered Modernization Platform in the new AWS Marketplace AI Agents and Tools category
- OysterLink Reports Surge in Controversial Restaurant Fee Talks
- PRIVACY ALERT: House of Dior Under Investigation for Data Breach of Customer Records
- KORE to Report Second Quarter 2025 Results on August 14, 2025
Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
Published on Thu 1 May 2025 9:22:08 UTC
More Post from the Author
- Broadridge Schedules Webcast and Conference Call to Review Fourth Quarter and Fiscal Year 2025 Results on August 5, 2025
- AveriSource announces availability of AI-Powered Modernization Platform in the new AWS Marketplace AI Agents and Tools category
- OysterLink Reports Surge in Controversial Restaurant Fee Talks
- PRIVACY ALERT: House of Dior Under Investigation for Data Breach of Customer Records
- KORE to Report Second Quarter 2025 Results on August 14, 2025